OptiNose (OPTN) Trading 6.9% Higher

OptiNose Inc (NASDAQ:OPTN) shares traded up 6.9% during mid-day trading on Thursday . The stock traded as high as $28.73 and last traded at $28.46. 501,554 shares traded hands during mid-day trading, an increase of 236% from the average session volume of 149,181 shares. The stock had previously closed at $26.62.

Several research analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of OptiNose from a “sell” rating to a “hold” rating in a research note on Friday, June 15th. ValuEngine upgraded shares of OptiNose from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $29.25.

The company has a debt-to-equity ratio of 0.57, a quick ratio of 9.50 and a current ratio of 9.66. The firm has a market cap of $1.02 billion and a price-to-earnings ratio of -5.06.

OptiNose (NASDAQ:OPTN) last released its quarterly earnings data on Monday, May 14th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.07). The firm had revenue of $0.87 million for the quarter. analysts anticipate that OptiNose Inc will post -3.15 EPS for the current fiscal year.

In related news, Director Robert P. O’neil acquired 2,000 shares of the firm’s stock in a transaction dated Friday, June 8th. The stock was purchased at an average cost of $22.75 per share, with a total value of $45,500.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Sriram Venkataraman sold 2,875,000 shares of the company’s stock in a transaction that occurred on Monday, June 11th. The shares were sold at an average price of $20.92, for a total transaction of $60,145,000.00. The disclosure for this sale can be found here. 67.80% of the stock is owned by insiders.

Hedge funds have recently made changes to their positions in the business. California State Teachers Retirement System purchased a new stake in OptiNose during the fourth quarter valued at approximately $162,000. TIAA CREF Investment Management LLC purchased a new stake in OptiNose during the fourth quarter valued at approximately $173,000. Teachers Advisors LLC purchased a new stake in OptiNose during the fourth quarter valued at approximately $184,000. Millennium Management LLC purchased a new stake in OptiNose during the fourth quarter valued at approximately $190,000. Finally, Deutsche Bank AG purchased a new stake in OptiNose during the fourth quarter valued at approximately $247,000. 29.63% of the stock is owned by institutional investors and hedge funds.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply